State Street Corp Decreases Holdings in Stevanato Group S.p.A. (NYSE:STVN)

State Street Corp trimmed its position in shares of Stevanato Group S.p.A. (NYSE:STVN) by 7.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 214,157 shares of the company’s stock after selling 17,026 shares during the quarter. State Street Corp’s holdings in Stevanato Group were worth $4,283,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Natixis Advisors LLC lifted its stake in shares of Stevanato Group by 27.3% in the 2nd quarter. Natixis Advisors LLC now owns 42,674 shares of the company’s stock worth $783,000 after purchasing an additional 9,146 shares during the period. Comgest Global Investors S.A.S. boosted its stake in shares of Stevanato Group by 56.8% during the 2nd quarter. Comgest Global Investors S.A.S. now owns 394,120 shares of the company’s stock worth $7,228,000 after acquiring an additional 142,754 shares during the last quarter. TD Asset Management Inc grew its position in shares of Stevanato Group by 324.2% during the 2nd quarter. TD Asset Management Inc now owns 108,853 shares of the company’s stock valued at $1,996,000 after acquiring an additional 83,191 shares during the period. General American Investors Co. Inc. increased its stake in shares of Stevanato Group by 9.4% in the 2nd quarter. General American Investors Co. Inc. now owns 328,179 shares of the company’s stock worth $6,019,000 after purchasing an additional 28,179 shares in the last quarter. Finally, Thornburg Investment Management Inc. raised its holdings in Stevanato Group by 279.1% in the 2nd quarter. Thornburg Investment Management Inc. now owns 746,218 shares of the company’s stock worth $13,690,000 after purchasing an additional 549,378 shares during the period.

Stevanato Group Price Performance

NYSE:STVN opened at €21.61 ($22.51) on Monday. The stock has a market cap of $6.39 billion, a PE ratio of 45.98, a P/E/G ratio of 10.49 and a beta of 0.59. The company has a quick ratio of 1.21, a current ratio of 1.81 and a debt-to-equity ratio of 0.22. The business’s 50-day simple moving average is €20.34 and its two-hundred day simple moving average is €19.86. Stevanato Group S.p.A. has a 52 week low of €16.56 ($17.25) and a 52 week high of €34.73 ($36.18).

Stevanato Group (NYSE:STVN) last issued its earnings results on Tuesday, November 5th. The company reported €0.12 ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of €0.13 ($0.14) by (€0.01) (($0.01)). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The business had revenue of €277.90 million for the quarter, compared to the consensus estimate of €274.36 million. During the same period last year, the business posted $0.16 EPS. The firm’s revenue for the quarter was up 2.4% compared to the same quarter last year. As a group, analysts forecast that Stevanato Group S.p.A. will post 0.5 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on the company. Morgan Stanley reissued an “equal weight” rating and set a $23.00 price target (down previously from $24.00) on shares of Stevanato Group in a report on Tuesday, December 3rd. Wolfe Research assumed coverage on Stevanato Group in a research note on Friday, December 13th. They set an “outperform” rating and a $28.00 price objective for the company. Finally, Bank of America raised their target price on shares of Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Stevanato Group currently has a consensus rating of “Moderate Buy” and a consensus price target of €28.60 ($29.79).

Stevanato Group Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.